SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Given Consensus Recommendation of “Buy” by Analysts

Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) have earned a consensus rating of “Buy” from the six analysts that are covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $68.00.

Several brokerages have commented on SWTX. Guggenheim began coverage on shares of SpringWorks Therapeutics in a research report on Monday, February 5th. They issued a “buy” rating and a $75.00 price objective on the stock. JPMorgan Chase & Co. lifted their price objective on shares of SpringWorks Therapeutics from $73.00 to $74.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 6th. HC Wainwright lifted their price objective on shares of SpringWorks Therapeutics from $73.00 to $74.00 and gave the stock a “buy” rating in a research report on Wednesday, March 6th. Barclays lifted their target price on shares of SpringWorks Therapeutics from $47.00 to $63.00 and gave the stock an “overweight” rating in a research note on Thursday, February 29th. Finally, Wedbush lifted their target price on shares of SpringWorks Therapeutics from $60.00 to $70.00 and gave the stock an “outperform” rating in a research note on Monday, February 26th.

Insider Transactions at SpringWorks Therapeutics

In related news, insider Daniel Pichl sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $50.10, for a total transaction of $751,500.00. Following the completion of the transaction, the insider now owns 45,212 shares of the company’s stock, valued at $2,265,121.20. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 7.61% of the company’s stock.

Hedge Funds Weigh In On SpringWorks Therapeutics

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in SpringWorks Therapeutics by 0.4% during the third quarter. Vanguard Group Inc. now owns 4,922,462 shares of the company’s stock valued at $113,807,000 after acquiring an additional 20,651 shares in the last quarter. Walleye Capital LLC lifted its position in SpringWorks Therapeutics by 196.8% during the third quarter. Walleye Capital LLC now owns 144,307 shares of the company’s stock valued at $3,336,000 after purchasing an additional 95,694 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in SpringWorks Therapeutics by 16.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 423,764 shares of the company’s stock valued at $9,797,000 after purchasing an additional 59,138 shares during the last quarter. Fiera Capital Corp lifted its position in SpringWorks Therapeutics by 2.9% during the third quarter. Fiera Capital Corp now owns 892,934 shares of the company’s stock valued at $20,645,000 after purchasing an additional 25,510 shares during the last quarter. Finally, Swiss National Bank lifted its position in SpringWorks Therapeutics by 0.9% during the third quarter. Swiss National Bank now owns 75,600 shares of the company’s stock valued at $1,748,000 after purchasing an additional 700 shares during the last quarter.

SpringWorks Therapeutics Price Performance

SWTX opened at $40.10 on Friday. The company’s 50-day moving average is $47.96 and its 200 day moving average is $37.07. SpringWorks Therapeutics has a fifty-two week low of $18.00 and a fifty-two week high of $53.92. The firm has a market capitalization of $2.96 billion, a P/E ratio of -7.80 and a beta of 0.83.

SpringWorks Therapeutics (NASDAQ:SWTX) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($1.24) by ($0.20). The business had revenue of $5.45 million for the quarter, compared to analyst estimates of $1.26 million. During the same quarter last year, the company posted ($1.19) earnings per share. On average, equities research analysts expect that SpringWorks Therapeutics will post -4.71 earnings per share for the current year.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.